Acadia's Nuplazid Could Have The Alzheimer's R&D Curse
Executive Summary
Acadia's Nuplazid (pimavanserin) has met its primary endpoint in a Phase II study in patients with Alzheimer’s disease psychosis – but a secondary endpoint miss in the same study has triggered alarm bells for future development of the product in Alzheimer's, a historically risky scene, marred by many Phase III failures.
You may also be interested in...
Stockwatch: 2017, Year Of The Dog
News in the life sciences sector over the holiday period was peppered with clinical and regulatory failures at Acadia, Anthera, Opko and Cempra, and a drug pricing controversy from Biogen. Following underperformance in 2016 and with that sort of run-up, 2017 already looks likely to be another lost one.
Lilly’s Thanksgiving Turkey: Lessons From Another Failed Alzheimer’s Program
There was nothing to be thankful about from Lilly’s disclosure that its potential Alzheimer’s therapy solanezumab failed to demonstrate significant improvement in cognition in a third large Phase III trial. But it does reinforce the wisdom of FDA’s standards for subgroup analysis in failed trials.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.